Synthetic vs. natural/biodegradable polymers for delivery of shRNA-based Cancer Therapies

Methods in Molecular Biology

Volumn 480, Issue , 2009, Pages 11-29

  Vorhies, John S ^a   Nemunaitis, John J ^a  

^a Mary Crowley Medical Research Center   (United States)

Author keywords

Biodegradable polymer; Drug delivery; Microparticle; Nanoparticle; Natural polymer; Non viral gene delivery; RNAi; ShRNA; Synthetic polymer; Tumor targeting

Indexed keywords

EID: 84934440974     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-59745-429-2_2     Document Type: Article

References (81)

1. Matzke, M.A., and Birchler, J.A. (2005) RNAi-mediated pathways in the nucleus. Nature Reviews 6:24-35.
2. Paddison, P.J., Caudy, A.A., Bernstein, E., Hannon, G.J., and Conklin, D.S. (2002) Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes and Development 16:948-958.
3. Stein, U., Walther, W., Stege, A., Kaszubiak, A., Fichtner, I., and Lage, H. (2008) Complete in vivo reversal of the multidrug resistance phenotype by jet-injection of anti-MDRl short hairpin RNA-encoding plasmid DNA. Molecular Therapy 16(1):178-186.
4. Lage, H. (2005) Potential applications of RNA interference technology in the treatment of cancer. Future Oncology 1:103-113.
5. Bantounas, I., Phylactou, L.A., and Uney, J.B. (2004) RNA interference and the use of small interfering RNA to study gene function in mammalian systems. Journal of Molecular Endocrinology 33:545-557.
6. Wadhwa, R., Kaul, S.C., Miyagishi, M., and Taira, K. (2004) Vectors for RNA interference. Current Opinion in Molecular Therapeutics 6:367-372.
7. Marsden, P.A. (2006) RNA interference as potential therapy-not so fast. The New England Journal of Medicine 355:953-954.
8. Balter, M. (2000) Gene therapy on trial. Science 288:951-957.
9. Check, E. (2002) A tragic setback. Nature 420:116-118.
10. Nishikawa, M., and Hashida, M. (2002) Nonviral approaches satisfying various requirements for effective in vivo gene therapy. Biological and Pharmaceutical Bulletin 25:275-283.
11. Dang, J.M., and Leong, K.W. (2006) Natural polymers for gene delivery and tissue engineering. Advanced Drug Delivery Reviews 58:487-499.
12. Storrie, H., and Mooney, D.J. (2006) Sustained delivery of plasmid DNA from polymeric scaffolds for tissue engineering. Advanced Drug Delivery Reviews 58:500-514.
13. Tiera, M.J., Winnik, F.O., and Fernandes, J.C. (2006) Synthetic and natural polycations for gene therapy: state of the art and new perspectives. Current Gene Therapy 6:59-71.
14. Park, T.G., Jeong, J.H., and Kim, S.W. (2006) Current status of polymeric gene delivery systems. Advanced Drug Delivery Reviews 58:467-486.
15. Schwartz, B., Ivanov, M.A., Pitard, B., Escriou, V., Rangara, R., Byk, G., Wils, P., Crouzet, J., and Scherman, D. (1999) Synthetic DNA-compaeting peptides derived from, human sequence enhance cationic lipid-mediated gene transfer in vitro and in vivo. Gene Therapy 6:282-292.
16. Plank, C., Mechtler, K., Szoka Jr., F.C., and Wagner, E. (1996) Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. Human Gene Therapy 7:1437-1446.
17. Chonn, A., Cullis, P.R., and Devine, D.V. (1991) The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. Journal of Immunology 146:4234-4241.
18. Kircheis, R., Blessing, T., Brunner, S., Wightman, L., and Wagner, E. (2001) Tumor targeting with surface-shielded ligand-polycation DNA complexes. Journal of Controlled Release 72:165-170.
19. Barron, L.G., Gagne, L., and Szoka Jr., F.C. (1999) Lipoplex-mediated gene delivery to the lung occurs within 60 minutes of intravenous administration. Human Gene Therapy 10:1683-1694.
20. Boussif, O., Lezoualc'h, F., Zanta, M.A., Mergny, M.D., Scherman, D., Demeneix, B., and Behr, J.P. (1995) A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proceedings of the National Academy of Sciences of the United States of America 92:7297-7301.
21. Venturoli, D., and Rippe, B. (2005) Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability. American Journal of Physiology Renal Physiology 288:F605-F613.
22. Dreher, M.R., Liu, W., Michelich, C.R., Dewhirst, M.W., Yuan, F., and Chilkoti, A. (2006) Tumor vascular permeability, accumulation, and penetration of macro-molecular drug carriers. Journal of the National Cancer Institute 98:335-344.
23. Greish, K. (2007) Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. Journal of Drug Targeting 15:457-464.
24. Schatzlein, A.G., Zinselmeyer, B.H., Elouzi, A., Dufes, C., Chim, Y.T., Roberts, C.J., Davies, M.C., Munro, A. et al. (2005) Preferential liver gene expression with polypropylenimine dendrimers. Journal of Controlled Release 101: 247-258.
25. Hughes, J.A., and Rao, G.A. (2005) Targeted polymers for gene delivery. Expert Opinion on Drug Delivery 2:145-157.
26. Singh, M. (1999) Transferrin as a targeting ligand for liposomes and anticancer drugs. Current Pharmaceutical Design 5:443-451.
27. Li, D., Wang, Q.Q., Tang, O.P., Huang, H.L., Shen, F.P., Li, J.Z., and Yu, H. (2006) Receptor-mediated gene delivery using polyethylenimine (PEI) coupled with polypeptides targeting FGF receptors on cells surface. Journal of Zhejiang University Science B 7:906-911.
28. Liu, X., Tian, P., Yu, Y., Yao, M., Cao, X., and Gu, J. (2002) Enhanced autitumor effect of EGF R-targeted p21 WAF-1 and GM-CSF gene transfer in the established murine hepatoma by peritumoral injection. Cancer Gene Therapy 9: 100-108.
29. Backer, M.V., Gaynutdinov, T.I., Patel, V., Bandyopadhyaya, A.K., Thirumamagal, B.T., Tjarks, W., Barth, R.F., Claffey, K., and Backer, J.M. (2005) Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Molecular Cancer Therapeutics 4:1423-1429.
30. Hilgenbrink, A.R., and Low, P.S. (2005) Folate receptor-mediated drug targeting: from therapeutics to diagnostics. Journal of Pharmaceutical Science 94: 2135-2146.
31. Anwer, K., Logan, M., Tagliaferri, F., Wadhwa, M., Monera, O., Tung, C.H., Chen, W., Leonard, P. et al. (2000) Synthetic glycopeptide-based delivery systems for systemic gene targeting to hepatocytes. Pharmaceutical Research 17: 451-459.
32. Mori, T. (2004) Cancer-specific ligands identified from screening of peptide-display libraries. Current Pharmaceutical Design 10:2335-2343.
33. Lee, J.F., Stovall, G.M., and Ellington, A.D. (2006) Aptamer therapeutics advance. Current Opinion in Chemical Biology 10:282-289.
34. Nimjee, S.M., Rusconi, C.P., and Sullenger, B.A. (2005) Aptamers: an emerging class of therapeutics. Annual Review of Medicine 56:555-583.
35. Ireson, C.R., and Kelland, L.R. (2006) Discovery and development of anticancer aptamers. Molecular Cancer Therapeutics 5:2957-2962.
36. Hicke, B.J., Stephens, A.W., Gould, T., Chang, Y.F., Lynott, C.K., Heil, J., Borkowski, S., Hilger, C.S. et al. (2006) Tumor targeting by an aptamer. Journal of Nuclear Medicine 47:668-678.
37. Perkins, A.C., and Missailidis, S. (2007) Radiolabelled aptamers for tumour imaging and therapy. The Quarterly Journal of Nuclear Medicine and Molecular Imaging 51:292-296.
38. Dufes, C., Uchegbu, I.F., and Schatzlein, A.G. (2005) Dendrimers in gene delivery. Advanced Drug Delivery Reviews 57:2177-2202.
39. Urdea, M.S., and Horn, T. (1993) Dendrimer development. Science 261:534.
40. Alper, J. (1991) Rising chemical "stars" could play many roles. Science 251: 1562-1564.
41. Bielinska, A.U., Chen, C., Johnson, J., and Baker Jr., J.R. (1999) DNA complexing with polyamidoamine dendrimers: implications for transfection. Bioconjugate Chemistry 10:843-850.
42. Majoras, I.J., Thomas, T.P., Mehta, C.B., and Baker Jr., J.R. (2005) Poly (amidoamine) dendrimer-based multifunctional engineered nanodevice for cancer therapy. Journal of Medicinal Chemistry 48:5892-5899.
43. Shukla, R., Thomas, T.P., Peters, J.L., Desai, A.M., Kukowska-Latallo, J., Patri, A.K., Kotlyar, A., and Baker Jr., J.R. (2006) HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. Bioconjugate Chemistry 17: 1109-1115.
44. Tsutsumi, T., Hirayama, F., Uekama, K., and Arima, H. (2008) Potential use of polyamidoamine dendrimer/alpha-cyclodextrin conjugate (generation 3, G3) as a novel carrier for short hairpin RNA-expressing plasmid DNA. Journal of Pharmaceutical Science 97(8):3022-3034.
45. Tack, F., Bakker, A., Maes, S., Dekeyser, N., Bruining, M., Elissen-Roman, C., Janicot, M., Brewster, M. et al. (2006) Modified polypropylene imine) dendrimers as effective transfection agents for catalytic DNA enzymes (DNAzymes). Journal of Drug Targeting 14:69-86.
46. Garnett, M.C. (1999) Gene-delivery systems using cationic polymers. Critical Reviews in Therapeutic Drug Carrier System 16:147-207.
47. Wightman, L., Kircheis, R., Rossler, V., Carotta, S., Ruzicka, R., Kursa, M., and Wagner, E. (2001) Different behavior of branched and linear polyethylenimine for gene delivery in vitro and in vivo. The Journal of Gene Medicine 3:362-372.
48. Jeong, J.H., Song, S.H., Lim, D.W., Lee, H., and Park, T.G. (2001) DNA transfection using linear poly(ethylenimine) prepared by controlled acid hydrolysis of poly(2-ethyl-2-oxazoline). Journal of Controlled Release 73:391-399.
49. Petersen, H., Fechner, P.M., Martin, A.L., Kunath, K., Stolnik, S., Roberts, C.J., Fischer, D., Davies, M.C., and Kissel, T. (2002) Polyethylenimine-graft-poly(ethylene glycol) copolymers: influence of copolymer block structure on DNA complexation and biological activities as gene delivery system. Bioconjugate Chemistry 13:845-854.
50. Chiu, S.J., Ueno, N.T., and Lee, R.J. (2004) Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin) conjugated polyethylenimine. Journal of Controlled Release 97:357-369.
51. Merdan, T., Callahan, J., Petersen, H., Kunath, K., Bakowsky, U., Kopeckova, P., Kissel, T., and Kopecek, J. (2003) Pegylated polyethylenimine- Fab' antibody fragment conjugates for targeted gene delivery to human ovarian carcinoma cells. Bioconjugate Chemistry 14:989-996.
52. Min, S.H., Lee, D.C., Lim, M.J., Park, H.S., Kim, D.M., Cho, C.W., Yoon, D.Y., and Yeom, Y.I. (2006) A composite gene delivery system consisting of polyethylenimine and an amphipathic peptide KALA. The Journal of Gene Medicine 8:1425-34.
53. Guan, H., Zhou, Z., Wang, H., Jia, S.F., Liu, W., and Kleinerman, E.S. (2005) A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model. Clinical Cancer Research 11:2662-2669.
54. Paranjpe, S., Bowen, W.C., Bell, A.W., Nejak-Bowen, K., Luo, J.H., and Michalopoulos, G.K. (2007) Cell cycle effects resulting from inhibition of hepatocyte growth factor and its receptor c-Met in regenerating rat livers by RNA interference. Hepatology (Baltimore, Md) 45:1471-1477.
55. Hassani, Z., Francois, J.C., Alfama, G., Dubois, G.M., Paris, M., Giovannangeli, C., and Demeneix, B.A. (2007) A. hybrid CMV-H1 construct improves efficiency of PEI-delivered shRNA in the mouse brain. Nucleic Acids Research 35:e65.
56. Yamagata, M., Kawano, T., Shiba, K., Mori, T., Katayama, Y., and Niidome, T. (2007) Structural advantage of dendritic poly(L-lysine) for gene delivery into cells. Bioorganic and Medicinal Chemistry 15:526-532.
57. Moriguchi, R., Kogure, K., Akita, H., Futaki, S., Miyagishi, M., Taira, K., and Harashima, H. (2005) A multifunctional envelope-type nano device for novel gene delivery of siRNA plasmids. International Journal of Pharmaceutics 301:277-285.
58. Sano, A., Maeda, M., Nagahara, S., Ochiya, T., Honma, K., Itoh, H., Miyata, T., and Fujioka, K. (2003) Atelocollagen for protein and gene delivery. Advanced Drug Delivery Reviews 55:1651-1677.
59. Wang, J., Lee, I.L., Lim, W.S., Chia, S.M., Yu, H., Leong, K.W., and Mao, H.Q. (2004) Evaluation of collagen and methylated collagen as gene carriers. International Journal of Pharmaceutics 279:115-126.
60. Cohen-Sacks, H., Elazar, V., Gao, J., Golomb, A., Adwan, H., Korchov, N., Levy, R.J., Berger, M.R., and Golomb, G. (2004) Delivery and expression of pDNA embedded in collagen matrices. Journal of Controlled Release 95: 309-320.
61. Coester, C.J., Langer, K., van Briesen, H., and Kreuter, J. (2000) Gelatin, nanoparticles by two step desolvation - a new preparation method, surface modifications and cell uptake. Journal of Microencapsulation 17:187-193.
62. Zwiorek, K., Kloeckner, J., Wagner, E., and Coester, C. (2005) Gelatin nanoparticles as a new and simple gene delivery system. Journal of Pharmacy and Pharaceutical Science 7:22-28.
63. Coester, C. (2003) Development of a new carrier system for oligonucleotides and Plasmids based on gelatin nanoparticles. New Drugs 1:14-17.
64. Kushibiki, T., Nagata-Nakajima, N., Sugai, M., Shimizu, A., and Tabata, Y. (2006) Enhanced anti-fibrotic activity of plasmid DNA expressing small interference RNA for TGF-beta type II receptor for a mouse model of obstructive nephropathy by cationized gelatin prepared from different amine compounds. Journal of Controlled Release 110:610-617.
65. Matsumoto, G., Kushibiki, T., Kinoshita, Y., Lee, U., Omi, Y., Kubota, E., and Tabata, Y (2006) Cationized gelatin delivery of a plasmid DNA expressing small interference RNA for VEGF inhibits murine squamous cell carcinoma. Cancer Science 97:313-321.
66. Chandy, T., and Sharma, C.P. (1990) Chitosan - as a biomaterial. Biomaterials, Artificial Cells, and Artificial Organs 18:1-24.
67. Howard, K.A., Rahbek, U.L., Liu, X., Damgaard, C.K., Glud, S.Z., Andersen, M.O., Hovgaard, M.B., Schmitz, A. et al. (2006) RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Molecular Therapy 14:476-484.
68. Katas, H., and Alpar, H.O. (2006) Development and characterisation of chitosan nanoparticles for siRNA delivery. Journal of Controlled Release 115:216-225.
69. Agnihotri, S.A., Mallikarjuna, N.N., and Aminabhavi, T.M. (2004) Recent advances on chitosan-based micro- and nanoparticles in drug delivery. Journal of Controlled Release 100:5-28.
70. Mansouri, S., Lavigne, P., Corsi, K., Benderdour, M., Beaumont, E., and Fernandes, J.C. (2004) Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy. European Journal of Pharmaceutics and Biopharmaceutics 57:1-8.
71. Leong, K.W., Mao, H.Q., Truong-Le, V.L., Roy, K., Walsh, S.M., and August, J.T. (1998) DNA-polycation nanospheres as non-viral gene delivery vehicles. Journal of Controlled Release 53:183-193.
72. Borchard, G. (2001 ) Chitosans for gene delivery. Advanced Drug Delivery Reviews 52:145-150.
73. Koping-Hoggard, M., Tubulekas, I., Guan, H., Edwards, K., Nilsson, M., Varum, K.M., and Artursson, P. (2001) Chitosan as a nonviral gene delivery system. Structure-property relationships and characteristics compared with polyethylenimine in vitro and after lung administration in vivo. Gene Therapy 8:1108-1121.
74. Hwang, S.J., Bellocq, N.C., and Davis, M.E. (2001) Effects of structure of beta-cyclodextrin-containing polymers on gene delivery. Bioconjugate Chemistry 12:280-290.
75. Pun, S.H., Bellocq, N.C., Liu, A., Jensen, G., Machemer, T., Quijano, E., Schluep, T., Wen, S. et al. (2004) Cyclodextrin-modified polyethylenimine polymers for gene delivery. Bioconjugate Chemistry 15:831-840.
76. Hedley, M.L. (2003) Formulations containing poly(lactide-co-glycolide) and plasmid DNA expression vectors. Expert Opinion on Biological Therapy 3:903-910.
77. Dhiman, N., Dutta, M., and Khuller, G.K. (2000) Poly (DL-lactide-co- glycolide) based delivery systems for vaccines and drugs. Indian Journal of Experimental Biology 38:746-752.
78. Singh, M., Fang, J.H., Kazzaz, J., Ugozzoli, M., Chesko, J., Malyala, P., Dhaliwal, R., Wei, R. et al. (2006) A modified process for preparing cationic polylactide-co-glycolide microparticles with adsorbed DNA. International Journal of Pharmaceutics 327:1-5.
79. Cheng, J., Teply, B.A., Sherifi, I., Sung, J., Luther, G., Gu, F.X., Levy-Nissenbaum, E., Radovic-Moreno, A.F. et al. (2007) Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28: 869-876.
80. Niola, F., Evangelisti, C., Campagnolo, L., Massalini, S., Bue, M.C., Mangiola, A., Masotti, A., Maira, G. et al. (2006) A plasmid-encoded VEGF siRNA reduces glioblastoma angiogenesis and its combination with interleukin-4 blocks tumor growth in a xenograft mouse model. Cancer Biology and Therapy 5:174-179.
81. Kushibiki, T., Nagata-Nakajima, N., Sugai, M., Shimizu, A., and Tabata, Y. (2005) Delivery of plasmid DNA expressing small interference RNA for TGF-beta type II receptor by cationized gelatin to prevent interstitial renal fibrosis. Journal of Controlled Release 105:318-331.